MSU
DMAAR

Mizuho Securities USA’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Mizuho Securities USA’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-209,897
Closed -$21K – 753
2025
Q2 		$21K Hold
209,897
– – ﹤0.01% 659
2025
Q1 		$21K Buy
+209,897
New +$29.5K ﹤0.01% 620

Other funds holding DMAAR

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
HCI
Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Mizuho Securities USA's DMAAR Position: Q3 2025 in Review

Mizuho Securities USA sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q3 2025, closing a stake of 209,897 shares — an estimated $21K sold.

Mizuho Securities USA first reported a position in DMAAR in Q1 2025 and held it in 2 quarters. The position peaked at $21K in Q2 2025. 32 funds tracked by Wall St. Rank hold DMAAR as of Q3 2025.

  • Mizuho Securities USA reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q3 2025 after selling out during the quarter.
  • Mizuho Securities USA sold 209,897 Drugs Made In America Acquisition Corp Rights shares in Q3 2025, an estimated $21K.
  • Mizuho Securities USA first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 2 quarters.
  • Mizuho Securities USA's Drugs Made In America Acquisition Corp Rights position peaked at $21K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2025.

Based on Mizuho Securities USA's 13F filing for Q3 2025, filed 22 Oct 2025.